As the President and Founder of PHASTAR, Kevin Kane leverages his extensive expertise in statistics and clinical trial management to drive innovation in the biopharmaceutical industry. With a strong entrepreneurial spirit, Kevin has established PHASTAR as a leading provider of statistical consulting and clinical trial...
As the President and Founder of PHASTAR, Kevin Kane leverages his extensive expertise in statistics and clinical trial management to drive innovation in the biopharmaceutical industry. With a strong entrepreneurial spirit, Kevin has established PHASTAR as a leading provider of statistical consulting and clinical trial data analysis services, catering specifically to the unique needs of biotech and pharmaceutical companies. His commitment to delivering error-free results on time is not just a personal obsession; it is a core value that permeates the company’s culture and operational processes.
Under Kevin's leadership, PHASTAR has undertaken numerous key projects that exemplify the company's capabilities in managing complex clinical trial programs. By employing a standardized approach to data analysis and collection, PHASTAR ensures that clients receive consistent, high-quality results that facilitate informed decision-making in drug development. Kevin's deep understanding of clinical development, particularly in oncology, has positioned PHASTAR as a trusted partner for organizations navigating the intricacies of cancer research and biopharmaceuticals.
Kevin's proficiency in SAS programming and CRO management further enhances PHASTAR's service offerings, allowing the company to provide tailored solutions that meet the diverse needs of its clients. His ability to blend technical statistical skills with strategic business management has not only fueled the growth of PHASTAR but has also contributed to the advancement of research and development in the pharmaceutical sector. As a thought leader in the industry, Kevin continues to advocate for innovative methodologies that improve the efficiency and effectiveness of clinical trials, ultimately striving to bring new therapies to market faster and more reliably.
